HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors

BACKGROUND: Nearly 30% of neuroendocrine tumors (NETs) have evidence of immunohistochemical (IHC) expression of estrogen (ER) and/or progesterone (PR) receptors. Therefore, targeting ER/PR may offer an effective NET-directed treatment to select patients. METHODS: We conducted a multicenter Simon two...

Descripción completa

Detalles Bibliográficos
Autores principales: Barros, Milton J., Strosberg, Jonathan, Al-Toubah, Taymeyah, de Jesus, Victor Hugo F., Durant, Lais, Mello, Celso A., Felismino, Tiago C., De Brot, Louise, Taboada, Rodrigo G., Donadio, Mauro D., Riechelmann, Rachel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Advances in Diagnosis and Treatment of Neuroendocrine Neoplasms
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387775/
https://www.ncbi.nlm.nih.gov/pubmed/37529158
http://dx.doi.org/10.1177/17588359231186041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387775/
https://www.ncbi.nlm.nih.gov/pubmed/37529158
http://dx.doi.org/10.1177/17588359231186041

Ejemplares similares